Skip to main content

Advertisement

SpringerLink
Log in

Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The optimal conversion ratio between Dysport and Botox—the two botulinum neurotoxin type A products (BoNT-As) supported by the larger bulk of evidence—has been extensively debated, because of its broad medical and economic implications. The article discusses the available evidence on the conversion ratio between Dysport and Botox in adults affected by spasticity, cervical dystonia, blepharospasm and hemifacial spasm, with a focus on clinical trials that specifically addressed this issue. In addition, some suggestions on the conversion ratio between Dysport and Xeomin can be extrapolated, since Xeomin has the same efficacy and safety profile as Botox and is exchangeable with Botox with a 1:1 conversion ratio. Taken together, the findings retrieved from this literature research suggest that a conversion ratio of 3:1 (Dysport:Botox)—or even lower—can be considered appropriate for the treatment of the above-mentioned conditions. Higher conversion ratios may lead to an overdosing of Dysport, with a potential increased incidence of adverse events. Therefore, we recommend that physicians using both products consider using a lower conversion factor as a guide, adjusting it upwards as required based on the specific characteristics and response to treatment of each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of commercial names is for communication purposes only and does not imply endorsement.

References

  1. De Maio M (2008) Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther 8:791–798

    Article  PubMed  Google Scholar 

  2. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB (2010) International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments—introduction. Eur J Neurol 17(Suppl 2):1–8

    Article  PubMed  Google Scholar 

  3. Brashear A (2010) Botulinum toxin type A: exploring new indications. Drugs Today (Barc) 46:671–682

    Article  CAS  Google Scholar 

  4. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584

    Article  PubMed  CAS  Google Scholar 

  5. Park J, Lee MS, Harrison AR (2011) Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol 5:725–732

    PubMed  CAS  Google Scholar 

  6. Pickett A (2011) Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol 5:1287–1290

    Article  PubMed  CAS  Google Scholar 

  7. Jost WH, Blümel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67:669–683

    Article  PubMed  CAS  Google Scholar 

  8. Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761–1768

    Article  PubMed  Google Scholar 

  9. Dressler D (2010) Botulinum toxin for treatment of dystonia. Eur J Neurol 17(Suppl 1):88–96

    Article  PubMed  Google Scholar 

  10. Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin preparations. J R Soc Med 87:719

    PubMed  CAS  Google Scholar 

  11. Pickett A, O’Keeffe R, Panjwani N (2007) The protein load of therapeutic botulinum toxins. Eur J Neurol 14:e11

    Article  PubMed  CAS  Google Scholar 

  12. Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255:1932–1939

    Article  PubMed  CAS  Google Scholar 

  13. Wohlfarth K, Muller C, Sassin I et al (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30:86–94

    Article  PubMed  CAS  Google Scholar 

  14. Hesse S, Lücke D, Malezic M et al (1994) Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 57:1321–1324

    Article  PubMed  CAS  Google Scholar 

  15. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 61:30–35

    Article  PubMed  CAS  Google Scholar 

  16. Simpson DM, Alexander DN, O’Brien CF et al (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306–1310

    Article  PubMed  CAS  Google Scholar 

  17. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69:217–221

    Article  PubMed  CAS  Google Scholar 

  18. Bakheit AM, Thilmann AF, Ward AB et al (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402–2406

    Article  PubMed  CAS  Google Scholar 

  19. Hyman N, Barnes M, Bhakta B et al (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707–712

    Article  PubMed  CAS  Google Scholar 

  20. Pittock SJ, Moore AP, Hardiman O et al (2003) A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 15:289–300

    Article  PubMed  CAS  Google Scholar 

  21. Woldag H, Hummelsheim H (2003) Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 50:165–171

    Article  PubMed  CAS  Google Scholar 

  22. Childers MK, Brashear A, Jozefczyk P et al (2004) Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 85:1063–1069

    Article  PubMed  Google Scholar 

  23. Brin MF (1997) Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 6:S208–S220

    Article  PubMed  CAS  Google Scholar 

  24. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462

    PubMed  CAS  Google Scholar 

  25. Odergren T, Hjaltason H, Kaakkola S et al (1998) A , randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12

    Article  PubMed  CAS  Google Scholar 

  26. Nüssgens Z, Roggenkämper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197–199

    Article  PubMed  Google Scholar 

  27. Sampaio C, Ferreira JJ, Simões F et al (1997) DYSPORT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord 12:1013–1018

    Article  PubMed  CAS  Google Scholar 

  28. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 33:261–267

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Editorial assistance was provided by Luca Giacomelli, PhD, on behalf of inScience Communications, Springer Healthcare. This assistance was funded by Ipsen.

Conflict of interest

  Authors declare no conflicts of interest directly relevant to this study.

Author information

Authors and Affiliations

  1. Department of Neuroscience, Neurology and Neurophysiology Units, Ospedale Civile Santa Maria della Misericordia Hospital, ULSS 18 Rovigo, Viale Tre Martiri 140, 45100, Rovigo, Italy

    Roberta Ravenni

  2. UILDM, Verona, Italy

    Domenico De Grandis

  3. Department of Internal Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy

    Alberto Mazza

Authors
  1. Roberta Ravenni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico De Grandis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto Mazza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberta Ravenni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravenni, R., De Grandis, D. & Mazza, A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci 34, 1043–1048 (2013). https://doi.org/10.1007/s10072-013-1357-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-013-1357-1

Keywords

Search

Navigation